Valeant Pharmaceuticals deal to buy bowel-drug maker Salix may be trumped by another offer from UK firm Endo International.
Valeant Pharmaceuticals deal to buy bowel-drug maker Salix may be trumped by another offer from UK firm Endo International. The Wall Street Journal is reporting an unnamed source as revealing that Endo has offered a deal that would add around $1 billion on to the amount that Valeant had agreed to pay. None of the companies were available to comment. Valeant’s shares fell 3 per cent on the report.
